• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Covering All Bases With Pfizer as It Aggressively Pursues a Covid-19 Vaccine

PFE is collaborating with German drugmaker BioNTech in the effort to find a well tolerated, effective vaccine.
By STEPHEN GUILFOYLE
May 05, 2020 | 11:10 AM EDT
Stocks quotes in this article: PFE, BNTX, MRNA, JNJ, GILD, TSN

Confident aggression or is it aggressive confidence? I am not quite sure. I do know that I like very much what I hear from Pfizer (PFE) regarding that firm's collaboration with German drugmaker BioNTech (BNTX) in the effort to find a well tolerated, effective vaccine to aid in the global fight against Covid-19.

Oh, Pfizer reported quarterly earnings early last week. Interestingly, even though the firm did beat expectations for both earnings and revenue, that revenue decreased year over year, and the release actually served to put a halt to five week rally. The shares have traded sideways since. Even more interestingly, across business segments, there was nice growth in Internal Medicine, Oncology, and even in Rare Disease. Not so much in Vaccines, or Inflammation & immunology though.

The best part of what Pfizer put to the tape on earnings day, even if it was a generally good quarter, was the guidance. The firm reaffirmed the corporate outlook for both earnings and revenue for the full year. While that is a neat trick this quarter, that is not why I am here. That's not what provoked this piece on this Tuesday morning.

The Need For Speed

There are now more than 100 potential vaccines under development worldwide as science rises to the challenge of defending the human race. At least eight of these hopeful candidates are already in human trials. We have written often in this space on bio-tech firm Moderna (MRNA) . That firm actually went into human trials back in March and has come to an agreement with Swiss based Lonza Ltd. in order to increase scale rapidly should those trials proceed well. We have already discussed Johnson & Johnson (JNJ) , and that operation's plan to go into human trials by September if everything goes as planned. JNJ believes that the firm could produce between 600 million and 900 million doses by the end of Q1 2021.

That brings us to Pfizer. Last Tuesday (earnings day) Pfizer CEO Albert Bourla appeared in the financial media. Bourla spoke of "millions" of doses sometime this year and then hundreds of millions by next year. During the call, the firm indicated that there could be such a vaccine candidate that might be ready for emergency use in the U.S. late Q3 2020 into Q4. That's not just fast, that's incredibly fast. The very next day, Pfizer and BioNTech announced together that the very first humans had already been dosed in Germany for a Phase 1/2 clinical trial. Just 12 people. The plan was to get regulatory approval for testing BNT 162 in the U.S. as well.

This morning, Pfizer and BioNTech again announced jointly that human trials have now begun in the United States. In one respect, this effort is barking up the same tree as the effort made by Moderna. That is the use of messenger RNA. There has never been a vaccine developed through this method that has come to market, as vaccines have traditionally used weakened strains of a virus in order to provoke immunity. The idea is that this kind of "high-tech" vaccine could instruct healthy immune systems to behave differently so that the infection can not make use of the proteins that it needs in order to invade and take over inside of an individual. Additional benefits should messenger RNA vaccines prove successful would be the increased speed of manufacture, as well as improved stability of the finalized product.

The Plan

The plan for Pfizer and BioNTech in the U.S. is to start with 360 healthy volunteers at the beginning and then, according to the New York Times, add up to 8,000 more by the end of the second stage. The need for so many is due to the fact that there will be several groups created so that four variations of the BNT 162 vaccine with slight differences in the formatting of genetic instructions to be followed by an individual's internal response.

The Chart

Well for one, shares of Pfizer do pay out $1.52 per year, so with a 4% yield, if this does not work out, the name can be placed in a revenue producing portfolio without a problem. What I see, even as Relative Strength improves, is the completion of a cup formation that has developed a short handle. If I am right, that puts the pivot at just about $39.25. We see failure there, the first line of support probably lines up at the 200 day SMA ($36.30). The daily MACD is extended so there is reason to think that this approach may fail on its first attempt.

On the other hand, should these shares show an ability to take the pivot, a $47 price target is realistic. My thought is this: With some exposure to Moderna and Johnson & Johnson, not to mention Gilead Sciences (GILD) , it probably isn't wise not to cover the bases, and covering the bases means including one of the largest U.S. drugmakers with a global reach and certainly a high level of confident aggression going into the project. Besides, I still have some Tyson Foods (TSN) to sell, and something to do with the cash created.

(Johnson & Johnson and Tyson Foods are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells these stocks? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long MRNA, JNJ, GILD, TSN equity.

TAGS: Drug Approvals | Earnings | Investing | Stocks | Technical Analysis | Trading | Pharmaceuticals | Coronavirus

More from Investing

Hopeful Investors Get Scraped by the Bear

James "Rev Shark" DePorre
Jun 28, 2022 4:24 PM EDT

Bulls hoped that a bottom had been found, but they overlooked the reasons behind the rally last week.

Bed Bath & Beyond's Weakness is Likely to Persist

Bruce Kamich
Jun 28, 2022 2:36 PM EDT

The shares have been in the single digits since early May.

Taking Another Look at ON Semiconductor's Charts

Bruce Kamich
Jun 28, 2022 1:43 PM EDT

Here's what to watch for.

Feeling Queasy Over Moderna's Outlook? Investors May Still Get Their Shot

Brad Ginesin
Jun 28, 2022 12:45 PM EDT

With an expected dip for 2023, the pharmaceutical company could see its mRNA technology win big over the long term -- and investors could be rewarded.

Penn National: Should Investors Put Their Chips Down?

Bruce Kamich
Jun 28, 2022 12:13 PM EDT

Let's check out the charts and indicators on this operator of casinos and racetracks.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:56 AM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    Check out what's going on in the Stocks Under $10 ...
  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login